MWM
VKTX icon

Meadowbrook Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Meadowbrook Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,205
Closed -$1.31M – 77
2025
Q4 		$1.31M Buy
+37,205
New +$1.32M 1.49% 17

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Meadowbrook Wealth Management's VKTX Position: Q1 2026 in Review

Meadowbrook Wealth Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 37,205 shares — an estimated $1.31M sold.

Meadowbrook Wealth Management first reported a position in VKTX in Q4 2025 and held it in 1 quarter. The position peaked at $1.31M in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Meadowbrook Wealth Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Meadowbrook Wealth Management sold 37,205 Viking Therapeutics shares in Q1 2026, an estimated $1.31M.
  • Meadowbrook Wealth Management first reported a position in Viking Therapeutics in Q4 2025 and held it in 1 quarter.
  • Meadowbrook Wealth Management's Viking Therapeutics position peaked at $1.31M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Meadowbrook Wealth Management's 13F filing for Q1 2026, filed 14 Apr 2026.